The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy

Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the infl...

Full description

Bibliographic Details
Main Authors: Wen Yin, Tianqi Xu, Mohamed Altai, Maryam Oroujeni, Jie Zhang, Anzhelika Vorobyeva, Olga Vorontsova, Sergey V. Vtorushin, Vladimir Tolmachev, Torbjörn Gräslund, Anna Orlova
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Pharmaceutics
Subjects:
HER2
affibody molecule
albumin-binding domain
drug conjugate
targeted therapy
mertansine
Online Access:https://www.mdpi.com/1999-4923/13/11/1974

Internet

https://www.mdpi.com/1999-4923/13/11/1974

Similar Items